Printer Friendly

FOREST LABORATORIES, INC. AND BOCK PHARMACAL COMPANY ANNOUNCE CO-PROMOTION AGREEMENT FOR FOREST'S LORCET(R) 10/650

NEW YORK, April 4 /PRNewswire/ -- Bock Pharmacal Company and Forest Laboratories, Inc. (AMEX: FRX) today announced an agreement to co-promote Lorcet(R) 10/650, the fastest growing prescription narcotic analgesic for the treatment of moderate to moderately severe pain.

Forest began marketing Lorcet 10/650 in September 1992. Over one million prescriptions were written for Lorcet 10/650 in 1994.

Bock's sales force of 240 sales professionals will immediately join Forest's 400 sales professionals to promote Lorcet 10/650 to primary care physicians, obstetricians and gynecologists.

"We welcome this opportunity to expand our relationship with Bock with whom we have a co-promotion agreement for Flumadine," said Howard Solomon, Forest's president and chief executive. "Their expertise and broad coverage of primary care physicians, obstetricians, and gynecologists should significantly increase Lorcet 10/650's exposure to target physicians for one of Forest's fastest growing products."

"It is certainly rewarding for Bock to forge alliances with companies as prestigious as Forest Laboratories," said Lawrence B. Moskoff, chairman and chief executive officer of Bock. "Based on our previous collaboration with Forest and our success in the field to date, we are confident that Bock is in a position to contribute to the future sales growth of Lorcet 10/650."

Forest Laboratories is a New York based international healthcare company that develops, manufactures and distributes both prescription and over-the-counter products to treat a wide range of illnesses. Forest's products are marketed principally in the United States and Europe.

Founded in 1945, Bock Pharmacal Company of St. Louis, MO, is a leader in the marketing and development of ethical, branded pharmaceutical products with an emphasis on women's health and respiratory products.
 -0- 4/4/95


/CONTACTS: Kenneth E. Goodman of Forest Laboratories, Inc., 212-224-6707; Kristin DiCarlo of Bock Pharmacal, 314-579-0770; or Liz Landy of Burns McClellan, 212-505-1919/

(FRX)

CO: Forest Laboratories, Inc.; Bock Pharmacal Company ST: New York, Missouri IN: MTC SU:

LG-HD -- NY030 -- 3968 04/04/95 10:49 EDT
COPYRIGHT 1995 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 4, 1995
Words:324
Previous Article:MARTIN F. PURIS NAMED CHAIRMAN, CHIEF EXECUTIVE AND CHIEF CREATIVE OFFICER OF LINTAS WORLDWIDE; KEN ROBBINS TO RETIRE
Next Article:NASA AWARDS MULTI-YEAR TELEVISION CONTRACT TO STELLACOM, INC.
Topics:

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters